THE MAIDSTONE POST-GRADUATE MEDICAL CENTRE TRUST

Registered charity 292529 · accounts filings on the Charity Commission register · also known as MAIDSTONE POSTGRADUATE CENTRE

The purpose of the postgraduate centre is to provide a teaching & education environment and to promote multi-disciplinary activities for the trust and other agencies.

Causes: Education/training · Other Charitable Purposes · Get email alerts

Latest income
£33k
Latest spending
£51k
Registered
1985
Accounts read
FY2024

Financial health, per its FY2024 accounts

The accounts state that the charity reported a deficit on unrestricted funds of £17,145 for the year ended 31 December 2024, resulting in a decrease in total unrestricted funds to £27,048. The trustees maintain that the charity has adequate resources to continue in operational existence for the foreseeable future, citing sufficient funds earned from national study days despite decreased income from pharmaceutical sponsors.

Automated summary of the FY2024 accounts; the evidenced findings below carry the verbatim passages.

What the accounts disclose

Largest income source: Donations and gifts
“Donations and gifts 25,479” — page 12
Per its FY2024 accounts as filed with the Charity Commission.

Accounts independently examined (not a full audit). Discloses 3 of 6 completeness components.

Trustees · trustee networks

Trustee list from the Charity Commission register (current, not historical).

Operates in: Kent

Income and spending

Financial year endIncomeSpending
31/12/2024£33k£51k
31/12/2023£34k£28k
31/12/2022£5k£12k
31/12/2021£690£6k
31/12/2020£3k£4k

Common questions

Is THE MAIDSTONE POST-GRADUATE MEDICAL CENTRE TRUST financially healthy?

Per its FY2024 accounts: The accounts state that the charity reported a deficit on unrestricted funds of £17,145 for the year ended 31 December 2024, resulting in a decrease in total unrestricted funds to £27,048. The trustees maintain that the charity has adequate resources to continue in operational existence for the foreseeable future, citing sufficient funds earned from national study days despite decreased income from pharmaceutical sponsors. Its FY2024 accounts were independently examined.